MAP2K7 and non-small cell lung carcinoma: The tolerance of radiotherapy in non-small cell lung cancer (NSCLC) patients is increased through the IL-6/MEK/ERK pathway by upregulation of PD-L1 and downregulation of NKG2D [47].